The sequential improvement in gross margin from 40.2% in 2024Q4 to 45.8% in 2027Q1 suggests a favorable product mix and cost efficiencies, likely stemming from higher-margin services and consumables. Operating margin expansion from 14.5% to 19.1% over the same period indicates that revenue growth is translating into disproportionate profit growth, a sign of scalable operations. However, the 2024Q4 net loss of -0.1% margin was an anomaly, and the subsequent recovery to 13.4% net margin by 2027Q1 underscores the earnings power of the core business.

The upward trajectory in ROIC and ROE, albeit from low levels, suggests that STERIS is recovering from a trough and beginning to generate returns above its cost of capital. The improvement is driven by margin expansion rather than asset turnover, as asset turnover remained stable around 0.15. With a fortress balance sheet and minimal debt, the company's returns are increasingly a function of operational performance, and continued margin gains could drive ROIC toward peer levels, though it still lags Waters' 20.1% ROIC.

The reduction in DSO from 80 to 59 days and DIO from 104 to 66 days over the observed period indicates improved working capital management, likely due to better collection processes and inventory optimization. The CCC compression from 149 to 93 days frees up cash and reduces the need for external financing, which is consistent with the company's strong cash generation. However, DPO data is incomplete for 2027Q1, so the full picture of supplier leverage remains unclear, but the trend suggests enhanced operational efficiency.

The dramatic deleveraging, with total debt falling from $3.4B to $243.4M, transforms the balance sheet into a fortress, providing substantial financial flexibility. Interest coverage of 17.87x in 2027Q1, up from 6.97x in 2024Q4, suggests that debt service is highly comfortable and refinancing risk is negligible. This low leverage may position STERIS to pursue strategic acquisitions or return capital to shareholders, but investors should monitor whether the company maintains this conservative posture or re-levers for growth.

The current ratio of 5.89 and quick ratio of 2.96 in 2027Q1 suggest that STERIS can comfortably cover short-term obligations even under stress, with a significant cash cushion. The increase in cash from $207M to $482M over the period reflects strong cash generation and minimal debt service requirements. This liquidity provides a buffer against operational disruptions, though the reliance on inventory (DIO of 76 days) means that a sudden demand shock could tie up cash, but the overall position appears resilient.